Modi’s ‘Made in India’ thrust to fuel growth prospects for the Indian Pharma (API) manufacturers

By: Pharma News | Views: 3566 | Date: 29-Sep-2014

Union government’s ‘Made in India’ emphasis could notch up the growth prospects for the Indian active pharmaceutical ingredient (API) manufacturers. It would also reduce the dependence on China for a range of excipients and intermediates, said Anjan K Roy, managing director, RL Fine Chem and member Karnataka Drugs and Pharmaceutical Manufacturers Association.


Modi’s ‘Made in India’ thrust to fuel growth prospects for the Indian Pharma (API) manufacturers

Centre’s‘Made in India’ thrust to fuel API sector growth & cut imports from China:Anjan K Roy


Union governent’s ‘Made in India’ emphasis could notch up the growth prospects for the Indian active pharmaceutical ingredient (API) manufacturers. It would also reduce the dependence on China for a range of excipients and intermediates, said Anjan K Roy, managing director, RL Fine Chem and member Karnataka Drugs and Pharmaceutical Manufacturers Association.

The API industry would see a further boost in terms of developing a strong product pipeline with the arrival of poly pills. There are several Indian API players engaged in advanced research of the active ingredients used to produce a combined tablet for blood pressure and cardiovascular disease. But since these companies are in the process of applying for patents, no details can be disclosed, he added.

However, what is encouraging is the new government’s efforts to take the right steps to encourage the domestic API, intermediate and excipients manufacturers and this is a positive move as much of these products are imported from China, Roy told Pharmabiz.

Indian API industry will be on a high growth trajectory by 2020 with the new government looking to encourage domestic manufacturing with a slew of benefits. This will see the sector augment its international presence. So long, all efforts were to allow China dominate in this space and Indian API sector was losing its ground. But now we see a turnaround as the sector is being recognised, he said. 

In the case of drug registration fees, the earlier government has maintained the skewed levy. For instance China could register in India for a $2,000 per drug. But India could register each drug at $20,000. Now the Union government is moving to increase the levy for the products from China.

China under the President Xi Jinping is looking to make its economy more dynamic by opening more industries to foreign competition. There are drugs like paracetamol and antibiotics where China has a clear edge. In the case of India, it is gaining ground to prove its expertise in oncology and neuropsychiatry APIs.

Further, there is also a big opportunity for Indian APIs to manufacture Angiotensin II receptor antagonists or sartans used in drugs for hypertension, diabetic nephropathy and congestive heart failure. Some of the APIs are osartan, candesartan, irbesartan, telmisartan, olmesartan, valsartan and eprosartan . India also has the expertise in dermatology and dental APIs. Therefore by 2020, Indian API industry could compete with China head on and be a preferred partner for global players in the space, Roy said.

 

Previous Page Next Page

People Searching On This Page:
  • all india pharma
  • Modi’s ‘Made in India’ thrust to fuel growth prospects for the Indian Pharma (API) manufacturers
  • indian

Related Pages


Indian Cabinet approve $750 mn investment by Mylan in India

Indian Cabinet approve $750 mn investment by Mylan in India

News | Pharma Companies
Date:
26-Nov-2015  Views: 15218

"The union cabinet, chaired by Prime Minister Narendra Modi, has approved $750-million FDI in Mylan Laboratories Ltd by Mylan Group through equity sha ...
Indian Pharma Expo - 2015

Indian Pharma Expo - 2015

News | Exhibitions & Conferences
Date:
31-Aug-2015  Views: 1565

Indian Pharma Expo 2015 provides an opportunity for the participating companies to display their products & services to the gamut of visitors, globall ...
Indian Immunologicals to set up a vaccine unit in Pondicherry

Indian Immunologicals to set up a vaccine unit in Pondicherry

News | Pharma Companies
Date:
16-Mar-2015  Views: 1580

The new plant will be set up with an investment of Rs 300 crore.Indian Immunologicals, part of the National Dairy Development Board, is setting up a n ...
Sun Pharma’s Dilip Shanghvi overtakes Mukesh Ambani as the richest Indian

Sun Pharma’s Dilip Shanghvi overtakes Mukesh Ambani as the richest Indian

News | Pharma Companies
Date:
26-Feb-2015  Views: 96664

Dilip Shanghvi, the 59-year-old promoter of Sun Pharma, appears to have overtaken Mukesh Ambani (57) of Reliance Industries Ltd (RIL) as the richest I ...
Indian Pharma Companies listed in 2-Billion Dollar Club

Indian Pharma Companies listed in 2-Billion Dollar Club

News
Date:
08-Sep-2014  Views: 2450

In 2013, there are three Indian Pharma companies that have crossed the coveted two-billion dollar mark in revenues. The latest or the most recent memb ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

62  + 1 =     
Comments
People Searched About:
All India Pharma   |   Modi’S ‘Made In India’ Thrust To Fuel Growth Prospects For The Indian Pharma (API) Manufacturers   |   Indian   |  
Google : 60 times | Yahoo : 23 times | Bing : 31 times |